MRI and ARIA Monitoring With At-Home Leqembi in 2026: Follow-Up Decisions People With Mild Cognitive Impairment May Need to Revisit

Plan MRI dates, ApoE testing, and symptom checks before starting weekly at-home Leqembi shots.

At-home Leqembi still requires clinic-based MRI monitoring for ARIA, a drug-related brain-swelling risk seen on scans. People with mild cognitive impairment starting the weekly shots will need to revisit MRI timing, genetic testing, and symptom plans.

Leqembi (lecanemab) is a treatment for early Alzheimer's disease, and ARIA means amyloid-related changes that can cause swelling or fluid buildup. The FDA approved once-weekly Leqembi Iqlik as an at-home starting dose that patients or caregivers can give without prior IV infusions, as described in the FDA approval notice. Eisai reports initiation uses two consecutive 250-mg autoinjector injections, each taking about 15 seconds, followed by 360-mg weekly maintenance.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What stays clinic-based with home dosing?

Home injections do not make treatment home-only. Eisai states treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid pathology. A clinic must still confirm eligibility, train the person giving shots, and review scans before dosing.

Experts cited by Medscape stress that scheduled imaging and clinician oversight continue after the move home, as summarized in their discussion of home lecanemab care. Families should keep the same imaging center, prescribing team, and after-hours contact. A missed MRI means a missed dosing decision.

When are follow-up MRIs due?

FDA labeling requires a recent baseline brain MRI plus scans after about 1, 2, 3, and 6 months, as listed in the current prescribing information. Each scan should occur generally within one week before the next dose and be reviewed before dosing. Book all four dates before the first shot.

The FDA added an earlier MRI before the third IV infusion in August 2025 because edema-related swelling or fluid buildup can require treatment changes. At-home patients should apply the same early-watch principle. Do not delay a scan because injections feel routine.

  • Baseline MRI: recent scan reviewed before starting
  • Month 1, 2, and 3 MRIs: early checks when swelling risk is highest
  • Month 6 MRI: later check to guide continued dosing

Who should revisit ApoE testing?

The FDA warns that ApoE ε4 homozygotes face higher rates of symptomatic, serious, and severe ARIA. The FDA places this group at about 15% of Alzheimer's patients and advises ApoE ε4 testing before starting. A prior decision to skip testing deserves a second look before home initiation.

A homozygote result means two copies of the risk gene, one from each parent. It does not bar treatment by itself. It changes counseling about ARIA signs, MRI adherence, and when to call urgently versus wait for the next visit.

What decisions may pause or stop dosing?

An MRI finding of swelling or fluid buildup can require a dose hold, added evaluation, or discontinuation. The at-home plan should name who reviews each scan, who tells the family, and what happens to that week's shots. Keep injections on hold until the team clears the scheduled dose.

Subcutaneous starting-dose approval rests on IV-trial benefit plus similar drug exposure and amyloid reduction, according to Drug Topics, not a separate outcomes trial. That makes follow-up imaging the main safety net for home starters. Bring the MRI schedule and ApoE result to each dosing visit.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.